Ling Chen

US Patent:

7655762, Feb 2, 2010

Filed:

Jan 6, 2006

Appl. No.:

11/327844

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/18

US Classification:

5303881, 5303879

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

8017733, Sep 13, 2011

Filed:

Jul 16, 2004

Appl. No.:

10/892830

Inventors:

KoChung Lin - Lexington MA, US
R. Blake Pepinsky - Arlington MA, US
Ling Ling Chen - Wellesley MA, US
Donna M. Hess - Waltham MA, US
Edward Y. Lin - Somerville MA, US
Russell C. Petter - Stow MA, US
Darren P. Baker - Hingham MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

C07K 17/08
C07K 14/565
C11D 3/38
C08G 59/00
C08G 59/14
C11D 3/386

US Classification:

530351, 435 6951, 436 86, 510320, 525525, 525526

Abstract:

The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.

US Patent:

8092796, Jan 10, 2012

Filed:

Dec 4, 2009

Appl. No.:

12/631598

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/18
A61K 39/395

US Classification:

4241301, 5303879, 5303881, 4241391, 4241411, 4241421, 4241331

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

8524660, Sep 3, 2013

Filed:

Sep 12, 2011

Appl. No.:

13/230080

Inventors:

KoChung Lin - Lexington MA, US
R. Blake Pepinsky - Arlington MA, US
Ling Ling Chen - Wellesley MA, US
Donna M. Hess - Waltham MA, US
Edward Y. Lin - Somerville MA, US
Russell C. Petter - Stow MA, US
Darren P. Baker - Hingham MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 47/48
C08G 65/329
A61K 38/00
C07K 17/08
A61K 31/00
A61K 38/21
C07K 14/565
C12N 15/22

US Classification:

514 43, 514 179, 514 37, 514 23, 514 11, 514 1, 435 6951, 436 86, 510320, 525525, 525526, 530351

Abstract:

The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.

US Patent:

8591891, Nov 26, 2013

Filed:

Dec 8, 2011

Appl. No.:

13/315027

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

A61K 39/395
C07K 16/18

US Classification:

4241301, 4241391, 4241411, 4241421, 4241331, 5303879, 5303881

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

20050058649, Mar 17, 2005

Filed:

Dec 2, 2003

Appl. No.:

10/726332

Inventors:

Gregory Landes - The Woodlands TX, US
Mary Haak-Frendscho - Newark CA, US
Ling Chen - The Woodlands TX, US
Meina Liang - Danville CA, US
Xiao Feng - Union City CA, US
Xiao-Chi Jia - Los Angeles CA, US
Mark Nocerini - San Francisco CA, US

International Classification:

A61K039/395
C07K016/40

US Classification:

424146100, 530388260

Abstract:

The invention described herein relates to antibodies directed to the antigen phospholipase A2 (PLA2) and uses of such antibodies. In particular, in accordance with some embodiments of the invention, there are provided fully human monoclonal antibodies directed to the antigen PLA2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

US Patent:

62076485, Mar 27, 2001

Filed:

Jul 17, 1998

Appl. No.:

9/118179

Inventors:

David J. Waxman - Newton MA
Ling Chen - Blue Bell PA

Assignee:

Trustees of Boston University - Boston MA

International Classification:

A01N43/04
7
C12N15/00
15/63
7
C07H21/04

US Classification:

514 44

Abstract:

Methods of killing neoplastic cells are provided. The invention relates to the use of NADPH-cytochrome P450 reductase (RED) gene transfer in combination with cytochrome P450 gene transfer to enhance the sensitivity of tumor cells to anti-cancer drugs that are activated by P450 enzymes. The use of bioreductive drugs that are activated by RED and/or cytochrome P450, in this paradigm, is also provided.

US Patent:

56887736, Nov 18, 1997

Filed:

Oct 28, 1994

Appl. No.:

8/330523

Inventors:

E. Antonio Chiocca - Boston MA
David J. Waxman - Newton Centre MA
Ming X. Wei - Somerville MA
Xandra O. Breakefield - Newton MA
Ling Chen - Brookline MA

Assignee:

The General Hospital Corporation - Boston MA
Boston University - Boston MA
Dana-Farber Cancer Institute - Boston MA

International Classification:

A61K 4800
C12N 500
C12N 1500
C07N 1400

US Classification:

514 44

Abstract:

A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.